Holen Sie sich die Stockscreener-App
3.3401
3.41%
0.1101
Handel nachbörslich:
3.34
-0.0001
-0.00%
Schlusskurs vom Vortag:
$3.23
Offen:
$3.23
24-Stunden-Volumen:
15,196
Relative Volume:
0.52
Marktkapitalisierung:
$514.00M
Einnahmen:
$117.10K
Nettoeinkommen (Verlust:
$-161.61M
KGV:
-1.3755
EPS:
-2.4283
Netto-Cashflow:
-
1W Leistung:
+2.77%
1M Leistung:
+1.83%
6M Leistung:
+63.73%
1J Leistung:
+24.17%
1-Tages-Spanne:
$3.23
$3.5299
1-Wochen-Bereich:
$3.1478
$3.5299
52-Wochen-Spanne:
$1.79
$5.45
Opthea Limited Adr Stock (OPT) Company Profile
Firmenname
Opthea Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
3.3401 | 514.00M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-26 | Eingeleitet | SVB Leerink | Outperform |
| 2020-11-17 | Eingeleitet | Citigroup | Buy |
| 2020-11-11 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-11 | Eingeleitet | SVB Leerink | Outperform |
| 2020-11-11 | Eingeleitet | Truist | Buy |
Alle ansehen
Opthea Limited Adr Aktie (OPT) Neueste Nachrichten
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea’s Wet AMD Program to be Featured at FLORetina 2024 - Yahoo Finance
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea Appoints Kathy Connell to Board of Directors - GlobeNewswire Inc.
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Sozinibercept Shows Superior Results in Phase 2b Eye Disease Trial - StockTitan
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
Opthea Files Notice of Annual General Meeting - The Manila Times
Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India
Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa
Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Joins the S&P/ASX 300 Index - StockTitan
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
EX-99.1 - SEC.gov
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
'Blockbuster opportunity': This speculative ASX stock could rise 70% - The Motley Fool Australia
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool
Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan
Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World
Finanzdaten der Opthea Limited Adr-Aktie (OPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):